Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose

BACKGROUND: Apramycin is under development for human use as EBL-1003, a crystalline free base of apramycin, in face of increasing incidence of multidrug-resistant bacteria. Both toxicity and cross-resistance, commonly seen for other aminoglycosides, appear relatively low owing to its distinct chemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Chenyan, Chirkova, Anna, Rosenborg, Staffan, Palma Villar, Rodrigo, Lindberg, Johan, Hobbie, Sven N, Friberg, Lena E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525081/
https://www.ncbi.nlm.nih.gov/pubmed/35849148
http://dx.doi.org/10.1093/jac/dkac225

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525081/
https://www.ncbi.nlm.nih.gov/pubmed/35849148
http://dx.doi.org/10.1093/jac/dkac225

Ejemplares similares